Sato Pharmaceutical Co. Ltd. and Eisai Co. Ltd., both of Tokyo, will co-promote BFE-1224 (fosravuconazole), a triazole class oral antifungal agent, in Japan. Sato will distribute the drug, while both companies will promote the drug. Eisai licensed BFE-1224 to Seren Pharmaceuticals Inc., of Tokyo, in 2010, which subsequently established a co-development agreement with Sato in 2014.